$LONA

LeonaBio, Inc. (LONA): Submission of Matters to a Vote of Security Holders

LeonaBio, Inc. (LONA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001620463 0001620463 2026-06-22 2026-06-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22,

Original reporting
Published Jun 23, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 23, 2026, 8:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$LONA
Neutral
high confidence
Mentioned
$LONA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$LONANeutralLow
01

Why it matters

The disclosure confirms: (1) election of three Class III directors, (2) ratification of Ernst & Young LLP as independent auditor for FY ending Dec. 31, 2026, and (3) advisory approval of executive compensation plus a non-binding preference for every 3 years for future advisory votes.

02

Market read

Routine governance outcomes; no new financial guidance, deal, or regulatory action is disclosed.

03

What to watch

Check the referenced May 11, 2026 proxy statement for any substantive proposals; this 8-K itself only reports final vote tallies.

Relevance 6/10Novelty 2/10Timing: after-hours/filing date (2026-06-23) for annual meeting vote results

Background

The company held its 2026 Annual Meeting on June 22, 2026 and filed an 8-K under Item 5.07 summarizing final voting results.

Company-level read

Ticker impact

$LONANeutralHigh confidence
Context

LeonaBio filed an 8-K reporting final shareholder vote results, including director elections and ratification of Ernst & Young for FY2026.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to governance/administrative sentiment.

Evidence & confidence

The filing only confirms voting outcomes (board seats, auditor ratification, advisory compensation items) and provides no new guidance, transactions, or enforcement developments.

Market effects

No meaningful read-across to the biotech sector; this is company-specific governance reporting.

None.

None.

Counterpoint

If investors were uncertain about auditor approval or board composition, the confirmed results could reduce uncertainty, but the filing still lacks fundamental catalysts.

Key entities

  • LeonaBio, Inc.

    Nasdaq-listed issuer filing Item 5.07 8-K with final annual meeting vote results.

  • Ernst & Young LLP

    Ratified as independent registered public accounting firm for fiscal year ending Dec. 31, 2026.

Related articles

$LONAMed

LeonaBio beats Q2 loss forecast as Phase 3 ELAINE-3 trial advances

LeonaBio (NASDAQ:LONA) reported a Q2 loss of $0.80 per share, smaller than analysts’ $1.12 forecast. Net loss rose to $19.0 million from $7.0 million a year earlier. Phase 3 ELAINE-3 enrollment nears 600 target, with 495 patients enrolled and topline results expected in H2 2027. Cash fell to $51.1 million from $88.3 million.

$LONAMed

LeonaBio, Inc. (LONA): Results of Operations and Financial Condition

LeonaBio, Inc. (LONA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline D

$CVXMedAI 8/10

Chevron (CVX) Supercharges its Venezuela Bet with More Oil Rigs

Chevron (CVX) plans to more than double its oil rigs in Venezuela, aiming to increase output to 600,000 barrels per day by 2031. The company has invested over $7 billion in joint ventures and expects low production costs below $20 per barrel. Despite risks, this expansion could significantly boost Chevron's earnings and cash flows, according to the company.

$CLFMedAI 8/10

How Investors Are Reacting To Cliffs Stock $1b Plant Upgrade

Cleveland-Cliffs announced a $1b modernization of its Middletown Works plant, supported by a $500m U.S. Department of Energy grant. The upgrade aims to improve efficiency and sustainability. The company reported a $866.0m loss and forecasts revenue growth of 6.6% annually, with earnings expected to improve to $1.1b by 2029. Analysts have set price targets ranging from $10.0 to $15.0, with a consensus target of $12.0.

$ZCSHMed

Grayscale Zcash ETF sets 3-for-1 share split

Grayscale's Zcash ETF (ZCSH) will undergo a 3-for-1 share split on Sept. 30, tripling shares without changing total value. Investors holding shares on Sept. 28 will receive two additional shares per existing share. The fund's assets grew rapidly since its Aug. 25 listing, reaching $890M by Sept. 17. ZCSH's price rose sharply before the split announcement, with ZEC also gaining.

$SYYMedAI 8/10

Debt Sale Could Be A Big Deal For Sysco Stock (SYY)

Sysco (SYY) completed a $1b equity offering and issued new fixed income securities, reshaping its capital structure for flexible funding. The company reaffirmed fiscal 2027 guidance of $90b in net sales, with 6-7% growth. Analysts forecast $96.1b revenue and $2.7b earnings by 2029. The move aims to support operations but also introduces balance sheet risks.